Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo Nordisk’s ...

Earnings date set: Hims & Hers will release Q1 2026 results on May 11, with consensus revenue near $616M and EPS at $0.13. Novo Nordisk pact: A March settlement allows sales of brand-name GLP-1 drugs, ...

Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report. The move caps a ...

Hims & Hers Health (HIMS) reported Q1 2026 earnings on May 11 and the stock dropped. Revenue of $608.1 million missed the $616.9 million estimate. The GAAP loss came in at $0.40 per share, far below ...

Digital health firm Hims & Hers' stock plummeted on Tuesday on weak first-quarter earnings. Hims reported a net loss of $92 million in the first quarter, up from $50 million last year. The company ...

News broke yesterday that the FDA is proposing to exclude the globally best-selling prescription drug molecules semaglutide, tirzepatide and liraglutide from its 503B bulk list, "finding no clinical ...